Pick the best stocks and maximize your portfolio: Novo Nordisk ( (NVO)) has provided an update. Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human ...
Novo Nordisk’s (NVO) semaglutide is a GLP-1 weight loss drug marketed as three separate brand name medications, Ozempic, Wegovy, and Rybelsus. Novo’s Wegovy competes with Eli Lilly’s (LLY) Zepbound.
A Danish court has sentenced a British hedge fund trader to 12 years in prison in connection with what authorities say was a 9 billion kroner ($1.3 billion) tax fraud, Danish justice officials confirm ...
4h
Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...
GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to ...
Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...
Stocks rebounded from a brief early August downturn fed by fears the Fed wouldn’t act quickly enough to stave off a recession ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback